Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of CAPOXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSGO).
Authors
Yoshinori Kagawa
Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan;
Yoshinori Kagawa , Chu Matsuda , Toshihiro Kudo , Yoshihiro Morimoto , Mitsuyoshi Tei , Yoshihito Ide , Norikatsu Miyoshi , Hidekazu Takahashi , Mamoru Uemura , Ichiro Takemasa , Taroh Satoh , Tsunekazu Mizushima , Kohei Murata , Yuichiro Doki , Hidetoshi Eguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000009974
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 109)
DOI
10.1200/JCO.2023.41.4_suppl.109
Abstract #
109
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
Poster
2021 ASCO Annual Meeting
Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.
First Author: Ji Zhu
Poster
2011 ASCO Annual Meeting
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer.
First Author: S. J. Wong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang